Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence

Cancer Treatment Reviews

Volumn 41, Issue 3, 2015, Pages 271-276

  Blok, E J ^a   Derks, M G M ^a   van der Hoeven, J J M ^a   van de Velde, C J H ^a   Kroep, J R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant endocrine therapy; Aromatase inhibitors; Biomarkers; Breast cancer; Extended treatment; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; LETROZOLE; NITRILE; PROGESTERONE RECEPTOR; TRIAZOLE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; EARLY CANCER; FEMALE; HORMONAL THERAPY; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; RECURRENCE RISK; REVIEW; RISK FACTOR; TREATMENT DURATION; BIOSYNTHESIS; BREAST NEOPLASMS; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 84923138537     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.02.004     Document Type: Review

References (71)

1. Pritchard K.I., Gelmon K.A., Rayson D., Provencher L., Webster M., McLeod D., et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 2013, 20(1).
2. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011 Aug 27, 378(9793):771-784.
3. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996 Oct 1, 14(10):2738-2746.
4. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816.
5. Gray R., Rea D., Handley K. ATTom: long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years in 6,953 women with early breast cancer. J Clin Oncol 2013, 31. (supplements; abstract 5).
6. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6, 349(19):1793-1802.
7. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896 Jul 18, 148(3803):162-165.
8. Pagani O., Regan M.M., Walley B.A., Fleming G.F., Colleoni M., Lang I., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 Jun 1, 371(2):107-118.
9. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971 Jun, 25(2):270-275.
10. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988 Dec 29, 319(26):1681-1692. Early Breast Cancer Trialists' Collaborative Group.
11. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996 Dec 18, 88(24):1834-1839. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group.
12. Sacco M., Valentini M., Belfiglio M., Pellegrini F., De Berardis G., Franciosi M., et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian interdisciplinary group for cancer evaluation study of adjuvant treatment in breast cancer 01. J Clin Oncol 2003 Jun 15, 21(12):2276-2281.
13. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996 Nov 6, 88(21):1543-1549. Swedish Breast Cancer Cooperative Group.
14. Smith I.E., Fitzharris B.M., Mckinna J.A., Fahmy D.R., Nash A.G., Neville A.M., et al. Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 1978 Sep 23, 312(8091):646-649.
15. Dowsett M. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol 1990 Dec 20, 37(6):1037-1041.
16. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002 Jun 22, 359(9324):2131-2139.
17. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5years' adjuvant treatment for breast cancer. Lancet 2005 Jan 1, 365(9453):60-62.
18. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010 Dec, 11(12):1135-1141.
19. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010 Jan 20, 28(3):509-518.
20. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M., et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377(9762):321-331.
21. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009 Aug 20, 361(8):766-776. The BIG 1-98 Collaborative Group.
22. Davidson N.E., O'Neill A.M., Vukov A.M., Osborne C.K., Martino S., White D.R., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005 Sep 1, 23(25):5973-5982.
23. Cuzick J., Ambroisine L., Davidson N., Jakesz R., Kaufmann M., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007 May 19, 369(9574):1711-1723. LHRH-agonists in Early Breast Cancer Overview group.
24. Malfetano J.H. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990 Oct, 39(1):82-84.
25. Magriples U., Naftolin F., Schwartz P.E., Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993 Mar 1, 11(3):485-490.
26. Fornander T., Cedermark Br., Mattsson A., Skoog L., Theve T., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989 Jan 21, 333(8630):117-120.
27. Duggan C., Marriott K., Edwards R., Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003 Oct 1, 21(19):3588-3593.
28. Meier C.R., Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998 Jun 1, 45(6):608-612.
29. Garreau J.R., DeLaMelena T., Walts D., Karamlou K., Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients perspective. Am J Surg 2006 Oct, 192(4):496-498.
30. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005 Jan 20, 23(3):619-629.
31. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003 Jun 12, 348(24):2431-2442.
32. Donnellan P.P., Douglas S.L., Cameron D.A., Leonard R.C.F. Aromatase inhibitors and arthralgia. J Clin Oncol 2001 May 15, 19(10):2767.
33. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., Howell A. Quality of life of postmenopausal women in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5-years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006, 100(3):273-284.
34. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2009, 381(9869):805-816.
35. Brewster A.M., Hortobagyi G.N., Broglio K.R., Kau S.W., Santa-Maria C.A., Arun B., et al. Residual risk of breast cancer recurrence 5years after adjuvant therapy. J Natl Cancer Inst 2008 Aug 20, 100(16):1179-1183.
36. Higgins M.J., Liedke P.E.R., Goss P.E. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol/Hematol 2013 Apr, 86(1):23-32.
37. Jin H., Tu D., Zhao N., Shepherd L.E., Goss P.E. Longer-term outcomes of letrozole versus placebo after 5years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012, 30:718-721.
38. Ingle J.N., Tu D., Pater J.L., Martino S., Robert N.J., Muss H.B., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006, 99:295-300.
39. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 2007 Dec 19, 99(24):1845-1853.
40. Markopoulos C., Dafni U., Misitzis J., Zobolas V., Tzoracoleftherakis E., Koukouras D., et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009, 11(3):R35.
41. Mamounas E.P., Jeong J.H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., et al. Benefit from exemestane as extended adjuvant therapy after 5years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 2008 Apr 20, 26(12):1965-1971.
42. Goss P, Mamounas E, Jakesz R, et al. Aromatase inhibitors (AIs) versus not (placebo/observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer (BC): overviews of randomized trials of AIs after ~5years of tamoxifen. Cancer Res 15.12.14;69(8), supplement 3. Ref Type: Abstract.
43. Burstein H.J., Temin S., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014 May 27.
44. Strasser-Weippl K., Badovinac-Crnjevic T., Fan L., Goss P.E. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast 2013, 22:S171-S175.
45. Bianchini G., Gianni L. An unmet need: tailoring extended adjuvant endocrine therapy. Br J Cancer 2013 Dec 10, 109(12):2951-2953.
46. Schiavon G., Smith I. Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 2014, 16(2):206.
47. Smith I.E., Yeo B., Schiavon G. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?. Am Soc Clin Oncol Educ Book 2014, e16-e24.
48. Mamounas E.P., Lembersky B., Jeong J.H., Cronin W., Harkins B., Geyer C., et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an ai in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006 Dec, 7(5):416-421.
49. NCT01064635: letrozole in treating breast cancer in postmenopausal women with Stage I, Stage II, or Stage III breast cancer previously treated with tamoxifen. 5.2.10. Ref Type: Internet Communication. http://clinicaltrials.gov/show/NCT01064635.
50. NCT00301457: different durations of adjuvant anastrozole therapy after 2 to 3 years tamoxifen therapy in breast cancer (DATA). 9.3.06. Ref Type: Internet Communication. http://clinicaltrials.gov/show/NCT00301457.
51. NCT00295620: secondary adjuvant long term study with arimidex (SALSA). 23.2.06. Ref Type: Internet Communication. http://clinicaltrials.gov/ct2/show/NCT00295620.
52. Fontein D.B.Y., Nortier J.W.R., Liefers G.J., Putter H., Meershoek-Klein Kranenbarg E., van den Bosch J., et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Eur J Surg Oncol (EJSO) 2012 Feb, 38(2):110-117.
53. International Breast Cancer Study Group. NCT00553410: letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, Early-Stage Breast Cancer (SOLE) 2.11.07; Ref Type: Internet Communication.
54. Cardoso F., Piccart-Gebhart M., Van't Veer L, Rutgers E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 2007 Dec, 1(3):246-251.
55. Ma C.X., Sanchez C.G., Ellis M.J. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 2009 Feb, 23(2):133-142.
56. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'orto P., et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26:5569-5575.
57. van de Water W., Fontein D.B.Y., van Nes J.G.H., Bartlett J.M.S., Hille Ee T.M., Putter H Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer: a TEAM study analysis. Eur J Cancer 2013 Jan, 49(2):297-304.
58. Wright C., Nicholson S., Angus B., Sainsbury J.R., Farndon J., Cairns J., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992 Jan, 65(1):118-121.
59. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008 Apr 1, 29(2):217-233.
60. Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005 Jan 15, 11(2):70s-865s.
61. Delpech Y., Wu Y., Hess K.R., Hsu L., Ayers M., Natowicz R., et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2012 Sep, 135(2):619-627.
62. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007 Jan 17, 99(2):167-170.
63. Cuzick J., Dowsett M., Pineda S., Wale C., Salter J., Quinn E., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011 Nov 10, 29(32):4273-4278.
64. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008 Mar 1, 26(7):1059-1065.
65. Barton S., Zabaglo L., A'Hern R., Turner N., Ferguson T., O'Neill S., et al. Assessment of the contribution of the IHC4+ C score to decision making in clinical practice in early breast cancer. Br J Cancer 2012 May 22, 106(11):1760-1765.
66. Dowsett M., Salter J., Zabaglo L., Mallon E., Howell A., Buzdar A.U., et al. Predictive algorithms for adjuvant therapy: transATAC. Steroids 2011 Jul, 76(8):777-780.
67. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008 Oct 1, 100(19):1380-1388.
68. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006 Oct, 7(4):347-350.
69. Dubsky P., Brase J.C., Jakesz R., Rudas M., Singer C.F., Greil R., et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013 Dec 10, 109(12):2959-2964.
70. Sestak I., Cuzick J., Dowsett M., Lopez-Knowles E., Filipits M., Dubsky P., et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 2014 Oct 20.
71. Sestak I., Dowsett M., Zabaglo L., Lopez-Knowles E., Ferree S., Cowens J.W., et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013 Oct 2, 105(19):1504-1511.